Healthcare Industry News: gastrointestinal stromal tumor
News Release - August 5, 2016
Teva Announces Launch of Generic Gleevec(R) Tablets in the United StatesJERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the launch of the generic equivalent to Gleevec®1(imatinib mesylate) tablets,100 mg and 400 mg, in the United States for multiple indications approved by the FDA.
Teva remains committed to strengthening its generics business with continued investment in new and diverse, high quality products. With nearly 375 generic medicines available, Teva has one of the largest portfolios of FDA-approved generic products on the market. The addition of this product to Teva’s oncology portfolio allows Teva to continue to grow in this therapeutic area.
Imatinib mesylate tablets had annual sales of approximately $2.42 billion in the United States, according to IMS data as of May 2016.
About Imatinib Mesylate Tablets
Imatinib mesylate tablets are indicated for: newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; patients with Ph+ CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy; adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia; adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements; adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown; adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRa fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRa fusion kinase negative or unknown; adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans; and adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive gastrointestinal stromal tumors (GIST) .
Important Safety Information
Serious adverse reactions associated with imatinib mesylate treatment include: edema and severe fluid retention; anemia, neutropenia, and thrombocytopenia; severe congestive heart failure and left ventricular dysfunction; severe hepatotoxicity, including fatalities; Grade 3/4 hemorrhage in patients with newly diagnosed CML and with GIST; gastrointestinal perforations, including fatalities; cardiogenic shock/left ventricular dysfunction in patients with conditions associated with high eosinophil levels; bullous dermatologic reactions, including erythema multiforme and Stevens-Johnson syndrome; hypothyroidism in thyroidectomy patients undergoing levothyroxine replacement; fetal harm when administered to a pregnant woman; growth retardation in children and pre-adolescents; and tumor lysis syndrome, including fatalities.
Reports of motor vehicle accidents have been received in patients receiving imatinib mesylate. Patients may experience dizziness, blurred vision or somnolence during treatment with imatinib mesylate. The most frequently reported adverse reactions (= 30%) for imatinib mesylate in clinical trials were: edema, nausea, vomiting, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue, and abdominal pain.
For more information, please see the accompanying Full Prescribing Information.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.
Source: Teva Pharmaceutical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.